Americans Are Spending the Most Money on These 25 Prescription Drugs

Note: This article is for general health and consumer education only. It is not medical advice. Never start, stop, switch, or ration a prescription medication without speaking with a licensed health professional.

Why America’s Prescription Drug Bill Keeps Growing

America does many things dramatically: skyscrapers, Super Bowl halftime shows, coffee sizes large enough to hydrate a small village, and, unfortunately, prescription drug spending. In 2023, U.S. prescription drug expenditures climbed to about $722.5 billion, a jump of 13.6% from the year before. That was not just a little bump in the road. It was the largest annual increase in two decades.

So, what happened? The short answer is that more people used more medicines, new high-cost therapies entered the market, and drug prices continued to rise. The longer answer is more interesting: the list of the most expensive prescription drugs in America reveals a health system wrestling with chronic disease, medical innovation, insurance complexity, and the uncomfortable fact that the most clinically exciting medications often arrive wearing very expensive shoes.

The 25 prescription drugs below are not ranked by how often they are prescribed. A low-cost blood pressure pill may be taken by millions of people and still not dominate national spending. Instead, this list reflects total U.S. spending, which means price, demand, insurance coverage, medical need, and market exclusivity all meet in one giant pharmacy receipt.

The 25 Prescription Drugs Americans Spent the Most Money On

Here are the top 25 prescription drugs by U.S. spending in 2023, based on national expenditure research. The names may look like someone dropped alphabet soup into a medical textbook, but each one tells a story about where American health care dollars are going.

What the List Reveals About American Health

1. Diabetes and Weight-Loss Drugs Are Reshaping the Market

Semaglutide took the top spot, and that is hardly surprising. Its brand names have become household words, whispered at dinner parties, discussed in doctor’s offices, debated on social media, and occasionally treated like celebrity gossip with a prescription label. Originally known mainly for type 2 diabetes treatment, semaglutide has also become closely associated with weight management and cardiovascular risk reduction.

The broader GLP-1 class, including semaglutide, dulaglutide, and tirzepatide, is changing the economics of prescription medicine. These drugs are expensive, widely discussed, and increasingly used for conditions that affect millions of Americans. When a medication moves from a specialized therapy to a mainstream health conversation, spending can accelerate faster than a shopping cart with one bad wheel.

2. Autoimmune Drugs Remain Budget Heavyweights

Adalimumab, better known as Humira, ranked second. For years, Humira was the reigning champion of prescription drug spending, and even as biosimilar competition has entered the market, autoimmune therapies still consume a large share of U.S. drug dollars.

These medicines are used for conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis. Many are biologics, meaning they are made through complex biological processes rather than simple chemical synthesis. Translation: they are not the kind of medicine you casually whip up in a lab next to the office coffee machine.

Other autoimmune and inflammatory disease drugs on the list include Stelara, Dupixent, Skyrizi, Enbrel, Cosentyx, and Taltz. Their presence shows how much spending is tied to long-term chronic conditions that often require ongoing treatment.

3. Blood Thinners Are a Major Cost Driver

Apixaban, sold as Eliquis, ranked third, while rivaroxaban, sold as Xarelto, also landed in the top 15. These medications are commonly used to reduce the risk of stroke and treat or prevent blood clots in certain patients.

The spending story here is simple: heart and vascular conditions are common, many patients take these medications long term, and brand-name pricing can add up quickly. For older adults especially, blood thinners can be medically important, but they also sit at the center of America’s affordability debate.

4. Cancer Immunotherapies Carry High Costs

Keytruda and Opdivo, both cancer immunotherapies, appear on the list because cancer treatment has entered an era of powerful but costly innovation. These drugs help the immune system recognize and attack certain cancers, and they have changed treatment possibilities for many patients.

That progress comes with a financial challenge. Oncology drugs are often expensive because they require years of research, complex trials, specialized manufacturing, and ongoing monitoring. In plain English: modern cancer therapy can be medically impressive and financially thunderous at the same time.

5. Insulin Still Matters in the National Spending Debate

Three insulin products appear in the top 25: insulin glargine, insulin aspart, and insulin lispro. That is a reminder that diabetes is not a niche issue in America. It is a daily reality for millions of people and a major force in national prescription drug spending.

Recent policy changes, including insulin cost caps for many Medicare beneficiaries, have helped some patients, but insulin affordability remains a closely watched issue. The larger lesson is that even older categories of medicine can remain expensive when demand is high and patients need them continuously.

Why Spending Rose So Fast in 2023

The rise in prescription drug spending was not caused by a single villain wearing a black cape and counting pills in a tower. It came from several forces moving at once.

More Use of Existing Drugs

Utilization was the biggest driver. When more people use a medication, or when a drug receives approval for additional conditions, spending rises. Wegovy’s expanded cardiovascular indication is a perfect example of how one new approved use can broaden the eligible patient population.

New Drugs Entering the Market

The FDA approved 55 novel drugs in 2023, including treatments aimed at serious or difficult conditions. New medications can bring genuine clinical value, especially when they address diseases with few options. But new also often means expensive, at least at first.

Price Increases

Prices also rose, though research suggests price changes were a smaller driver than utilization and new products. That distinction matters. The public conversation often focuses only on sticker prices, but the national spending total also reflects how many people use a drug, whether insurance covers it, whether competing products exist, and how long patients stay on therapy.

What This Means for Patients and Families

For patients, the national spending chart can feel abstract. A billion here, a billion there, and suddenly it sounds like the federal budget got stuck in the pharmacy aisle. But behind the numbers are ordinary people trying to manage diabetes, arthritis, heart disease, cancer, HIV, asthma, multiple sclerosis, immune disorders, and other serious conditions.

The practical takeaway is not that high-spending drugs are “bad.” Many are important therapies. The real issue is whether patients can access necessary treatment without facing impossible bills, confusing insurance denials, or delays that turn health care into a paperwork marathon.

Patients who struggle with prescription costs should talk with their doctor, pharmacist, or insurance plan before making any changes. In many cases, there may be safe alternatives, formulary options, biosimilars, generics, or plan-specific steps that can reduce costs. The key word is “safe.” Skipping doses or stopping medicine without guidance can be risky.

Policy Changes Are Starting to Matter

The Inflation Reduction Act introduced several prescription drug provisions affecting Medicare, including insulin cost caps, redesigned Part D out-of-pocket rules, and Medicare drug price negotiation. Negotiated prices for the first group of selected Medicare Part D drugs are scheduled to take effect in 2026.

Several drugs on the broader high-spending radar, including Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Stelara, NovoLog/Fiasp, and Imbruvica, were included in the first Medicare negotiation cycle. The long-term impact will depend on how negotiated prices, insurance formularies, manufacturer strategies, biosimilar competition, and patient demand interact.

In other words, the prescription drug market is not a straight line. It is more like a crowded airport security line: everyone is moving, everyone is carrying baggage, and nobody is completely sure why one lane is faster.

Experience: What America’s Prescription Drug Spending Feels Like in Real Life

Numbers like $38.58 billion for semaglutide or $35.33 billion for adalimumab can feel too large to understand. Most people do not walk around comparing billion-dollar drug categories over breakfast. Real life happens at the pharmacy counter, in the doctor’s office, during open enrollment, and in the quiet moment when someone opens an insurance letter and thinks, “Well, this looks expensive in three different fonts.”

Consider a common experience: a patient leaves a medical appointment relieved because there is finally a treatment plan. The doctor explains why the medication may help, the patient nods, and for a few minutes everything feels manageable. Then comes the pharmacy message: prior authorization required. Suddenly, the treatment plan has entered the insurance obstacle course, complete with invisible hurdles and hold music.

Another familiar situation involves switching insurance plans. A medication that was covered last year may move to a different tier, require new paperwork, or become subject to stricter approval rules. The patient did not change. The diagnosis did not change. The medicine did not grow a mustache and become a different product. Yet the cost can change dramatically because the plan design changed.

For people managing chronic disease, this uncertainty becomes exhausting. A person with diabetes may need glucose monitoring supplies, insulin, visits, lab tests, and possibly additional medications for blood pressure, cholesterol, kidney protection, or heart risk. A person with rheumatoid arthritis or Crohn’s disease may rely on a biologic to keep inflammation controlled and daily life functional. A cancer patient may face a treatment journey where the emotional and financial stakes are both high.

Families often become informal health care administrators. One person tracks refill dates. Another checks insurance mail. Someone calls the pharmacy. Someone else tries to understand the difference between deductible, copay, coinsurance, prior authorization, step therapy, and “please call your plan,” which may be the most stressful phrase in modern English.

The human experience behind prescription drug spending is not just about prices. It is about time, confusion, anxiety, and trust. Patients want to believe that if a medicine is medically necessary, the system will help them get it safely and affordably. When that does not happen smoothly, frustration grows.

Still, there is reason for cautious optimism. Biosimilars may increase competition for some biologic drugs. Medicare negotiation may reduce spending on selected medicines. Out-of-pocket caps may protect some patients from the worst annual costs. New therapies may prevent hospitalizations or improve quality of life. The best future is not one where innovation stops; it is one where innovation does not require patients to bring a magnifying glass, a calculator, and emotional support snacks to the pharmacy.

Conclusion

The 25 prescription drugs Americans spent the most money on in 2023 reveal the future of U.S. medicine: chronic disease treatment, biologics, cancer immunotherapy, diabetes care, weight-management therapies, and complex specialty drugs. These medications can be clinically meaningful, even life-changing, but their costs raise urgent questions about affordability, insurance design, competition, and public policy.

The headline is not simply that Americans spend a lot on prescription drugs. Everyone already knew the pharmacy receipt was not exactly shy. The deeper story is that spending is being driven by a mix of medical need, scientific progress, expanded use, and a system that still struggles to make breakthrough treatments financially reachable.

For patients, the safest move is to stay informed and work closely with health professionals. For policymakers, insurers, and drugmakers, the challenge is bigger: make sure the next generation of medicines does not arrive with a price tag that makes patients feel like they need a second prescription for sticker shock.